malignant hematological diseases
Conditions
Interventions
TM(L)I using IMRT with 3 Gy/fr, twice a day, 3 consecutive days 18 Gy in 6 fractions in total.
Sponsors
Murofushi Keiko
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Disease status is non-remission period, or predicted poor prognosis equivalent to High / Very high on the Refined disease risk index. 2. Aged from 16 to 59 years old. 3. ECOG Performance status of 0 - 2. 4. Adequate function of major organs within 28 days prior to study enrollment and met the following a)-h) criteria. a) Echocardiogram : Left ventricular cardiac ejection fraction of >= 50%. b) 12-lead electrocardiogram : No abnormal findings that require treatment. c) Arterial oxygen saturation >= 94% without inhaling oxygen. (Measurement by non-invasive oxygen saturation monitoring is also acceptable.) d) Pulmonary function test: %VC >= 70% and FEV1/FVC >= 70%. e) Serum total bilirubin == 30 mL/min. Predicted values based on Cockcroft-Gault equation are also acceptable. g) No diabetes mellitus poorly controlled with insulin. h) No psychiatric disorders requiring treatment with a major tranquilizer. 5. Written informed consent is obtained. If the case of a minor, the consent of a surrogate must be obtained.
Exclusion criteria
Exclusion criteria: 1. Patients not met the inclusion criteria. 2. Extramedullary or extranodal disease. 3. Synchronous or metachronous (within 5 years) malignancies. 4. Difficulty in maintaining rest during radiation therapy. 5. Patients who are technically difficult to irradiate with TomoTherapy (cannot fit in the treatment gantry, overweight, or difficult to calculate the dose). 6. Pregnant or potentially pregnant patients. 7. History of allogeneic or autologous transplantation. 8. Patients determined to be intolerant to hematopoietic stem cell transplantation, including chemotherapy and TMLI as a conditioning regimen. 9. Other conditions judged as inappropriate for the study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year overall survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Neutrophil/platelet engraftment rate 2. 2-year relapsed rate 3. 2-year non-relapse mortality rate 4. Incidence of acute GVHD of Grade II-IV 5. Incidence of chronic GVHD 6. Incidence of grade 3-5 adverse events between 3rd month and 2nd year after TM(L)I | — |
Contacts
Public ContactYuho Najima
Tokyo Metropolitan Komagome Hospital
Outcome results
None listed